| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2017 | 2016 | 2014 | 2013 | 2012 | 2011 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 27,1 M € | +86.2% | 14,5 M € | +4.3% | 13,9 M € | +0.9% | 13,8 M € | -39.2% | 22,7 M € | +0.5% | 22,6 M € | +259.2% | 6,3 M € | +24.6% | 5,1 M € | +44.4% | 3,5 M € | +100.8% | 1,7 M € | +8.2% | 1,6 M € | +119.5% | 734,0 k € | |
| EBITDA | 2,4 M € | +150.2% | 973,8 k € | +50.7% | 646,2 k € | -47.9% | 1,2 M € | -65.9% | 3,6 M € | +0.5% | 3,6 M € | +102.9% | 1,8 M € | +51.7% | 1,2 M € | -16.9% | 1,4 M € | +1113.3% | 116,4 k € | +133.8% | 49,8 k € | +128.4% | -175,3 k € | |
| Operating profit | 2,2 M € | +139.3% | 938,6 k € | +49.0% | 629,8 k € | -31.0% | 913,1 k € | -71.6% | 3,2 M € | -5.1% | 3,4 M € | +94.1% | 1,7 M € | +52.8% | 1,1 M € | -18.0% | 1,4 M € | +1554.9% | 84,1 k € | +156.8% | 32,8 k € | +117.6% | -186,7 k € | |
| Profit/loss | 1,6 M € | +131.5% | 695,9 k € | +24.9% | 557,2 k € | -18.3% | 682,2 k € | -72.5% | 2,5 M € | -0.1% | 2,5 M € | +116.5% | 1,1 M € | +51.8% | 755,6 k € | -15.8% | 897,2 k € | +1057.7% | 77,5 k € | +127.4% | 34,1 k € | +118.3% | -186,1 k € | |
| Equity | 8,1 M € | +24.9% | 6,5 M € | +12.1% | 5,8 M € | -33.8% | 8,7 M € | +8.5% | 8,0 M € | +44.7% | 5,6 M € | +34.1% | 4,1 M € | +38.3% | 3,0 M € | +166.4% | 1,1 M € | +397.9% | 225,5 k € | +52.4% | 148,0 k € | +29.9% | 113,9 k € | |
| Total assets | 16,2 M € | +76.4% | 9,2 M € | +6.2% | 8,7 M € | -14.3% | 10,1 M € | -21.3% | 12,9 M € | +53.2% | 8,4 M € | +47.8% | 5,7 M € | +18.5% | 4,8 M € | +177.5% | 1,7 M € | +108.7% | 826,6 k € | +55.5% | 531,5 k € | +97.4% | 269,2 k € | |
| Cash | 2,7 M € | +131.6% | 1,2 M € | +295.8% | 300,0 k € | -11.0% | 337,3 k € | — | 2,3 M € | +1717.8% | 124,0 k € | +79.0% | 69,2 k € | -74.2% | 268,4 k € | +97.9% | 135,6 k € | +36.6% | 99,3 k € | +494.4% | 16,7 k € | |||
| Debts | 7,6 M € | +209.4% | 2,4 M € | -11.7% | 2,8 M € | +134.8% | 1,2 M € | -74.9% | 4,7 M € | +65.4% | 2,8 M € | +85.7% | 1,5 M € | -14.9% | 1,8 M € | +198.2% | 602,7 k € | +2.8% | 586,1 k € | +52.8% | 383,5 k € | +147.7% | 154,8 k € | |
| Staff | 28,2 | 28,1 | 30,1 | 30,5 | 30,9 | 30,1 | 31,3 | 25,8 | 9,6 | 10,5 | 8,8 | 4,8 | ||||||||||||
Public limited company · Braine-l'Alleud · incorporated on 22/10/2010 · 28,2 ETP
Public limited company profitable and well capitalised. Cash position rising (+131.6%).
Solid counterparty for a standard engagement.
AXONE PHARMA is a Public limited company incorporated in 2010. Its main activity is: Agents specialised in the sale of other particular products. Its registered office is in Braine-l'Alleud. It employs on average 28,2 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette